Clinical trials: Relapsed
B-Cell Acute Lymphoblastic Leukaemia
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as…
- Trial name
- NCT07476729
- Testing
- Inotuzumab ozogamicin (INO), Blinatumomab
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 750 people
- Sponsor
- Charite University, Berlin, Germany
Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that…
- Conditions
- Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma
- Trial name
- NCT06620302
- Testing
- Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan
- Where
- 21 sites in United States
- Volunteers
- 81 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity…
- Trial name
- BEACON (NCT02308527)
- Testing
- Bevacizumab, Temozolomide, Irinotecan
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 225 people
- Sponsor
- University of Birmingham
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a…
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT02551718
- Testing
- Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Acute Myeloid Leukemia (AML)
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children.
- Trial name
- NCT06679582
- Testing
- Luveltamab tazevibulin
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 1 people
- Sponsor
- Sutro Biopharma, Inc.
B-Cell Leukemia, B-Cell Lymphoma
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
It is a single-center, open-labeled, single-arm, non-randomized, investigator-initiated trial aiming to evaluate the efficacy and safety of anti-CD19 CAR-T manufactured by OlyCAR platform (OlyCAR-019) for CD19+…
- Conditions
- B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors
- Trial name
- NCT05932173
- Testing
- Anti-CD19 Autologous CAR-T Cell Infusion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Relapsed or Refractory B Cell Leukemia and Lymphoma
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
- Trial name
- NCT06834529
- Testing
- CAR2219-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Urinary Tract Infections, Transplant-Related Disorder
Treatment Chronic UTI Post Kidney Transplant
Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E…
- Trial name
- NCT05967130
- Testing
- Phage
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.
- Conditions
- Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult, B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05648019
- Testing
- Anti-CD19 CAR T-cells
- Where
- 2 sites in Singapore
- Volunteers
- 40 people
- Sponsor
- KK Women's and Children's Hospital
Malignant Solid Tumor, Childhood Solid Tumor
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
This is a Phase I study of the combination of three drugs: sirolimus, cyclophosphamide, and topotecan. This is the first study to evaluate the safety and clinical activity of the combination of oral sirolimus, oral…
- Trial name
- NCT01670175
- Testing
- Sirolimus, Cyclophosphamide, Topotecan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Childhood Cancer, Childhood Solid Tumor
PRecISion Medicine for Children With Cancer
This is a multicentre prospective study of the feasibility and clinical value of a diagnostic service for identifying therapeutic targets and recommending personalised treatment for children and adolescents with high-risk cancer.
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Childhood Leukemia
- Trial name
- PRISM (NCT03336931)
- Testing
- Molecular profiling and drug testing
- Where
- 8 sites in Australia
- Volunteers
- 550 people
- Sponsor
- Sydney Children's Hospitals Network
Rhabdomyosarcoma
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
- Trial name
- FaR-RMS (NCT04625907)
- Testing
- Irinotecan, Actinomycin D, Doxorubicin
- Where
- 128 sites in Australia, Austria and 18 more
- Volunteers
- 1,672 people
- Sponsor
- University of Birmingham
CD7+ Acute Leukemia, CD7+ Lymphoma
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
This is a prospective, open-label, single-center clinical trial. This study will evaluate the safety and efficacy of anti-CD7 CAR-T cells in the treatment of relapsed or refractory CD7 positive T-ALL/LBL, T-NHL and AML.
- Trial name
- NCT04599556
- Testing
- anti-CD7 CAR-T
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Zhejiang University
Acute Lymphoblastic Leukemia
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
A retrospective analysis of historical data looking at hematological remission and survival in adult relapsed / refractory B-precursor acute lymphoblastic leukemia patients.
- Trial name
- NCT02003612
- Testing
- Not applicable - observational study
- Where
- 10 sites in United States, Czechia and 6 more
- Volunteers
- 2,373 people
- Sponsor
- Amgen
CNS 2a, CNS 2b
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of wee1 kinase inhibitor AZD1775 when given together with fludarabine, cytarabine, and filgrastim (FLAG) combination chemotherapy in treating children, adolescents and…
- Conditions
- CNS 2a, CNS 2b, CNS 2c, CNS1
- Trial name
- NCT02791919
- Testing
- Cytarabine, Filgrastim, Fludarabine Phosphate
- Sponsor
- National Cancer Institute (NCI)
T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
This is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies.
- Conditions
- T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
- Trial name
- NCT06316856
- Testing
- Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells
- Where
- 4 sites in China
- Volunteers
- 54 people
- Sponsor
- Beijing GoBroad Hospital
Hodgkin's Lymphoma
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is determine if 2 cycles of SGN-35 can be used instead of ICE prior to autologous stem cell transplant (ASCT) for relapsed and refractory HL.
- Trial name
- NCT01508312
- Testing
- brentuximab vedotin (SGN-35)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Vasculitis, Wegener's Granulomatosis
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
This study will compare the safety and effectiveness of two drugs-methotrexate and mycophenolate mofetil (MPM)-in preventing disease recurrence in patients with Wegener's granulomatosis and related inflammatory blood vessel…
- Trial name
- NCT00004567
- Testing
- Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Graft Versus Host Disease, Leukemia
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00265837
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroblastoma
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
RATIONALE: Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00450307
- Testing
- monoclonal antibody 3F8, sargramostim
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.